Human VE Cadherin DTSet enzyme-linked immunoassay kit

Product Features

• Optimized capture and detection antibody pairings with recommended concentrations save lengthy development time
• Development protocols are provided to guide further assay optimization
• Assay can be customized to your specific needs
• Economical alternative to complete kits

Kit Content

• Capture Antibody
• Detection Antibody
• Recombinant Standard
• Streptavidin conjugated to horseradish-peroxidase (Streptavidin-HRP)

Other Reagents Required

DTSet Ancillary Reagent Kit (5 plates): containing 96 well microplates, plate sealers, substrate solution, stop solution, plate coating buffer (PBS), wash buffer, and assay buffer.

• 96 well microplates: YOUKE Life, Catalog # DSEP01. Plate Sealers: YOUKE Life, Catalog # DSSF01.
• Coating Buffer: 137 mM NaCl, 2.7 mM KCl, 8.1 mM Na2HPO4, 1.5 mM KH2PO4, pH 7.2-7.4, 0.2 μm fi ltered . YOUKE Life, Catalog # DSCB01.
• Blocking Buffer: YOUKE Life, Catalog # DSBB01.
• Wash Buffer: 0.05% Tween 20 in PBS, pH 7.2-7.4. YOUKE Life, Catalog # DSWB01.
• Assay Buffer: 0.5%BSA，0.05%Tween20，PBS Solution.YOUKE Life, Catalog # DSAB01
• Substrate Solution: Tetramethylbenzidine. YOUKE Life, Catalog # DSTS01.
• Stop Solution: 0.5mol/ml H2SO4. YOUKE Life, Catalog # DSSS01.

Product Data Sheet

Background: VE Cadherin

The cadherin (Ca++-dependent adherence) superfamily is a large group of membrane-associated glycoproteins that engage in homotypic, calcium-dependent, cell-cell adhesion events. The superfamily can be divided into at least five major subfamilies based on molecule gene structure, and/or extracellular (EC) and intracellular domains (1-4). Subfamilies include classical/type I, atypical/type II, and desmosomal-related cadherins. VE-Cadherin (vascular endothelial cadherin; also cadherin-5 and CD144) is a 125 kDa atypical/type II subfamily cadherin. Its subfamily classification is based principally on its genomic structure, as its physical structure is notably divergent from other type II subfamily members. Mouse VE-Cadherin is synthesized as a 784 amino acid (aa) type I transmembrane (TM) preproprotein that contains a 24 aa signal peptide, a 21 aa prosequence, a 554 aa extracellular region (ECR), a 21 aa TM segment, and a 164 aa cytoplasmic domain. The ECR contains five Ca++-binding cadherin domains that are approximately 105 aa in length. Cadherin domains are comprised of two beta ‑sheets that are oriented like bread in a sandwich. Although complex, the N-terminal cadherin domain mediates trans interactions, while the internal domains contribute to cis multimerizations. Mouse VE-Cadherin ECR is 92%, 77%, and 73% aa identical to rat, human and porcine VE-Cadherin ECR, respectively. VE-Cadherin is involved in the maintenance of endothelial permeability. In this regard, VE-Cadherin does not initiate new blood vessel formation; it maintains it once formed. Thus, when VE‑Cadherin is downregulated, cells part and permeability increases. Notably, VEGF is known to promote vascular leakage, and apparently does so by inducing a beta ‑arrestin-dependent endocytosis of VE-Cadherin. Part of this effect may be mediated by VE‑Cadherin itself which is reported to increase the membrane half-life of VEGF R2. VE-Cadherin acts homotypically at sites of zonula adherens. On each expressing cell, it is proposed that VE-Cadherin first forms a trimer, which then dimerizes with a trimeric counterpart in-trans. Alternatively, two cis-dimers could act in-trans to generate homotypic binding. In addition to cell adhesion, VE‑Cadherin also is reported to mediate TGF-beta receptor assembly. When clustered, VE‑Cadherin enhances T beta RII/T beta RI assembly into an active receptor complex on endothelial cells. VE-Cadherin is expressed on endothelial cells, trophoblast cells, endothelial progenitor cells and embryonic hematopoietic cells.